Clinical Trial Update: Safety and Preliminary Efficacy of Recombinant Activated Factor VII in Subjects With Traumatic Brain Injury [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the safety and preliminary efficacy of recombinant activated factor VII in subjects with traumatic brain injury.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Traumatic Brain Injury

Drugs mentioned

• NovoSeven (recombinant coagulation factor VIIa)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Acquired Bleeding Disorder, Trauma | Phase 2 | Status: COMPLETED